Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Neijt

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 1, 1987
A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategyP F van Bommel, A C van Lindert, H C Kock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
Advanced ovarian cancer. Drug resistance, supportive care and dose intensityE G de Vries, T C Hamilton, M Lind, et al.
Lancet (London, England)|May 3, 1986
Complete remission at laparotomy: still a gold standard in ovarian cancer?J P Neijt, W W ten Bokkel Huinink, M E Van der Burg, et al.
Cancer Treatment Reports|February 1, 1980
Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatmentJ P Neijt, A C van Lindert, C P Vendrik, et al.
Progress in Clinical and Biological Research|January 1, 1985
Cytoreductive surgery with or without preceding chemotherapy in ovarian cancerJ P Neijt, E J Aartsen, J Bouma, et al.
European Journal of Gynaecological Oncology|January 1, 1988
The role of cytoreduction in ovarian cancerF Zanaboni, A P Heintz, J B Trimbos, et al.
The Netherlands Journal of Medicine|January 1, 1979
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and futureJ P Neijt, A C van Lindert, C P Vendrik, et al.
Journal of the Neurological Sciences|November 1, 1989
Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicityA Elderson, R Gerritsen van der Hoop, W Haanstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 20, 1980
[Chemotherapy of stage III and IV ovarian carcinoma]J P Neijt, J W Barents, C P Vendrik, et al.
Journal of Clinical Pathology|February 1, 1996
Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinomaM Brinkhuis, J P Baak, G A Meijer, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 1, 1987
A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategyP F van Bommel, A C van Lindert, H C Kock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
Advanced ovarian cancer. Drug resistance, supportive care and dose intensityE G de Vries, T C Hamilton, M Lind, et al.
Lancet (London, England)|May 3, 1986
Complete remission at laparotomy: still a gold standard in ovarian cancer?J P Neijt, W W ten Bokkel Huinink, M E Van der Burg, et al.
Cancer Treatment Reports|February 1, 1980
Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatmentJ P Neijt, A C van Lindert, C P Vendrik, et al.
Progress in Clinical and Biological Research|January 1, 1985
Cytoreductive surgery with or without preceding chemotherapy in ovarian cancerJ P Neijt, E J Aartsen, J Bouma, et al.
European Journal of Gynaecological Oncology|January 1, 1988
The role of cytoreduction in ovarian cancerF Zanaboni, A P Heintz, J B Trimbos, et al.
The Netherlands Journal of Medicine|January 1, 1979
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and futureJ P Neijt, A C van Lindert, C P Vendrik, et al.
Journal of the Neurological Sciences|November 1, 1989
Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicityA Elderson, R Gerritsen van der Hoop, W Haanstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 20, 1980
[Chemotherapy of stage III and IV ovarian carcinoma]J P Neijt, J W Barents, C P Vendrik, et al.
Journal of Clinical Pathology|February 1, 1996
Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinomaM Brinkhuis, J P Baak, G A Meijer, et al.
Pageof 10